← All trials
NCT05969236
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 6, 2023
- Primary completion
- Jul 31, 2024
- Completion date
- Oct 31, 2024
- First posted
- Aug 1, 2023
- Last posted
- Nov 22, 2023
- Enrollment
- 40
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Government of ChinaLead sponsor
- Government of ChinaStudy director
- CMAX Clinical ResearchOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.